Companies › Tetra Discovery Partners
1 active drug program in 1 registered trial: 1 Phase 3; Other; next expected readout Sep 2027.
Open in Phaseline: competitors, likelihood bands and readouts Company report
| Drug | Target | Highest phase | Conditions | Next expected readout |
|---|---|---|---|---|
| Zatolmilast (BPN14770) Phosphodiesterase 4D inhibitor | PDE4D | Phase 3 | Fragile X Syndrome | Sep 2027 |
| Registry id | Drug | Phase | Conditions | Area | Expected readout |
|---|---|---|---|---|---|
| NCT05367960 | Zatolmilast (BPN14770) | Phase 3 | Fragile X Syndrome | Other | Sep 2027 |
Mezzion Pharma Huons Biopharma Neuren Pharmaceuticals Prove pharm Neuraptive Therapeutics
Pipelines of the same shape: areas, drug types, target families, stage and cash runway.
Programs group the company's trials by drug; the target and mechanism come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood, shown as a band with its track record, is in the app.